{"id":892407,"date":"2025-10-03T21:45:05","date_gmt":"2025-10-04T01:45:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\/"},"modified":"2025-10-03T21:45:05","modified_gmt":"2025-10-04T01:45:05","slug":"uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\/","title":{"rendered":"UNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n NEW YORK<\/span>
\n <\/span>, Oct. 3, 2025<\/span><\/span> \/PRNewswire\/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of\u00a0Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024<\/span> and June 27, 2025<\/span>, both dates inclusive (the “Class Period”), of the important October 14, 2025<\/span> lead plaintiff deadline.<\/p>\n

\n

\n
\n \"LOGO
\n <\/a>\n <\/p>\n<\/p><\/div>\n

So what: If you purchased Unicycive securities\u00a0during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.<\/p>\n

What to do next: To join the Unicycive\u00a0class action, go to https:\/\/rosenlegal.com\/submit-form\/?case_id=44659<\/a>\u00a0mailto:<\/a>or call Phillip Kim, Esq.<\/span> toll-free at 866-767-3653 or email case@rosenlegal.com<\/a> for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 14, 2025<\/span>. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.<\/p>\n

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. <\/b>Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million<\/span> for investors. In 2020, founding partner Laurence Rosen<\/span> was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.<\/p>\n

Details of the case: According to the lawsuit, defendants \u00a0made false and\/or misleading statements and\/or failed to disclose that: (1) Unicycive’s readiness and ability to satisfy the U.S. Food and Drug Administration’s (“FDA”) manufacturing compliance requirements was overstated; (2) the oxylanthanum carbunate (“OLC”) New Drug Application’s (“NDA”) regulatory prospects were likewise overstated; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.<\/p>\n

To join the Unicycive class action, go to https:\/\/rosenlegal.com\/submit-form\/?case_id=44659<\/a> or\u00a0call Phillip Kim, Esq.<\/span> toll-free at 866-767-3653 or email case@rosenlegal.com<\/a> for information on the class action.<\/p>\n

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.<\/p>\n

Follow us for updates on LinkedIn: https:\/\/www.linkedin.com\/company\/the-rosen-law-firm<\/a>, on Twitter: https:\/\/twitter.com\/rosen_firm<\/a> or on Facebook: https:\/\/www.facebook.com\/rosenlawfirm\/<\/a>.<\/p>\n

Attorney Advertising. Prior results do not guarantee a similar outcome.<\/p>\n

——————————-<\/p>\n

Contact Information:<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0 Laurence Rosen, Esq.<\/span>
\u00a0\u00a0\u00a0\u00a0\u00a0 Phillip Kim, Esq.<\/span>
\u00a0\u00a0\u00a0\u00a0\u00a0 The Rosen Law Firm, P.A.
\u00a0\u00a0\u00a0\u00a0\u00a0 275 Madison Avenue, 40th Floor
\u00a0\u00a0\u00a0\u00a0\u00a0 New York, NY<\/span> 10016
\u00a0\u00a0\u00a0\u00a0\u00a0 Tel: (212) 686-1060
\u00a0\u00a0\u00a0\u00a0\u00a0 Toll Free: (866) 767-3653
\u00a0\u00a0\u00a0\u00a0\u00a0 Fax: (212) 202-3827
\u00a0\u00a0\u00a0\u00a0\u00a0 case@rosenlegal.com<\/a>
\u00a0\u00a0\u00a0\u00a0\u00a0 www.rosenlegal.com<\/a><\/p>\n

\u00a0<\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-302575117.html<\/a><\/p>\n

SOURCE THE ROSEN LAW FIRM, P. A.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK , Oct. 3, 2025 \/PRNewswire\/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of\u00a0Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”), of the important October 14, 2025 lead plaintiff deadline. So what: If you purchased Unicycive securities\u00a0during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Unicycive\u00a0class action, go to https:\/\/rosenlegal.com\/submit-form\/?case_id=44659\u00a0mailto:or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If … <\/p>\n

Continue reading “UNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-892407","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nUNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , Oct. 3, 2025 \/PRNewswire\/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of\u00a0Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”), of the important October 14, 2025 lead plaintiff deadline. So what: If you purchased Unicycive securities\u00a0during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Unicycive\u00a0class action, go to https:\/\/rosenlegal.com\/submit-form\/?case_id=44659\u00a0mailto:or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If … Continue reading "UNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-04T01:45:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"UNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit\",\"datePublished\":\"2025-10-04T01:45:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\\\/\"},\"wordCount\":621,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2598307\\\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\\\/\",\"name\":\"UNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2598307\\\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\",\"datePublished\":\"2025-10-04T01:45:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2598307\\\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2598307\\\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"UNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\/","og_locale":"en_US","og_type":"article","og_title":"UNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit - Market Newsdesk","og_description":"PR Newswire NEW YORK , Oct. 3, 2025 \/PRNewswire\/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of\u00a0Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”), of the important October 14, 2025 lead plaintiff deadline. So what: If you purchased Unicycive securities\u00a0during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Unicycive\u00a0class action, go to https:\/\/rosenlegal.com\/submit-form\/?case_id=44659\u00a0mailto:or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If … Continue reading \"UNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-04T01:45:05+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"UNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit","datePublished":"2025-10-04T01:45:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\/"},"wordCount":621,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\/","name":"UNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg","datePublished":"2025-10-04T01:45:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2598307\/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"UNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892407","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=892407"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892407\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=892407"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=892407"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=892407"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}